Conjugation of an antibody to cross-linked fibrin for targeted delivery of anti-restenotic drugs

Journal of Controlled Release

Volumn 100, Issue 3, 2004, Pages 357-377

  Thomas, Anita C ^a,b   Campbell, Julie H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Anti restenotic agent; Heparin; Immunoconjugate; Rapamycin; Targeted drug delivery

Indexed keywords

ARTERIES; NEOINTIMAL FORMATION; RESTENOSIS;

ANTIBODIES; CROSSLINKING; ORGANIC ACIDS; SURGERY;

DRUG PRODUCTS;

3 (2 PYRIDYLDITHIO)PROPIONIC ACID N HYDROXYSUCCINIMIDE ESTER; ADIPIC ACID DERIVATIVE; ADIPIC ACID DIHYDRAZIDE; ANTIBODY CONJUGATE; FIBRIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY H93 7C 1D2 48; RAPAMYCIN; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTERY INJURY; ARTICLE; CAROTID ARTERY; CELL DENSITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG PURIFICATION; DRUG TARGETING; INTIMA; NONHUMAN; PRIORITY JOURNAL; RABBIT; RESTENOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES; CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, ION EXCHANGE; CROSS-LINKING REAGENTS; DRUG DELIVERY SYSTEMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRIN; GRAFT OCCLUSION, VASCULAR; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; RABBITS; SIROLIMUS; SUCCINIMIDES;

EID: 9744282668     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.09.004     Document Type: Article

References (65)

1. M.R. Bennett, and M. O'Sullivan Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy Pharmacol. Ther. 91 2001 149 166
2. S.H. Duda, T.C. Poerner, B. Wiesinger, J.H. Rundback, G. Tepe, J. Wiskirchen, and K.K. Hasse Drug-eluting stents: potential applications for peripheral arterial occlusive disease J. Vasc. Interv. Radiol. 14 2003 291 301
3. Y.K. Ahn, M.H. Jeong, J.W. Kim, S.H. Kim, J.H. Cho, J.G. Cho, C.S. Park, S.W. Juhng, J.C. Park, and J.C. Kang Preventive effects of the heparin-coated stent on restenosis in the porcine model Catheter. Cardiovasc. Interv. 48 1999 324 330
4. J.E. Sousa, P.W. Serruys, and M.A. Costa New frontiers in cardiology. Drug-eluting stents: part 1 Circulation 107 2003 2274 2279
5. C. Indolfi, A. Mongiardo, A. Curcio, and D. Torella Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents Trends Cardiovasc. Med. 12 2003 142 148
6. D.W. Losordo, M.H. Isner, and L.J. Diaz-Sandoval Endothelial recovery. The next target in restenosis prevention Circulation 107 2003 2635 2637
7. A.L. Miller, F. Plane, J.Y. Jeremy, H.J. McKinnon, and C.L. Jackson Delayed recovery of receptor-mediated functional responses to acetylcholine in mouse isolated carotid arteries following endothelial denudation in vivo J. Vasc. Res. 40 2003 449 459
8. V.J. Dzau, R.C. Braun-Dullaeus, and D.G. Sedding Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies Nat. Med. 8 2002 1249 1256
9. H. Bult Restenosis: a challenge for pharmacology Trends Pharmacol. Sci. 21 2000 274 279
10. E.R. Edelman, and M.J. Karnovsky Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis Circulation 89 1994 770 776
11. M.A. Lovich, and E.R. Edelman Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo Proc. Natl. Acad. Sci. U. S. A. 96 1999 11111 11116
12. C. Rogers, M.J. Karnovsky, and E.R. Edelman Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration Circulation 88 1993 1215 1221
13. D. Brieger, and E. Topol Local drug delivery systems and prevention of restenosis Cardiovasc. Res. 35 1997 405 413
14. T. Suzuki, G. Kopia, S.-i. Hayashi, L.R. Bailey, G. Llanos, R. Wilensky, B.D. Klugherz, G. Papandreou, P. Narayan, M.B. Leon, A.C. Yeung, F. Tio, P.S. Tsao, R. Falotico, and A.J. Carter Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model Circulation 104 2001 1188 1193
15. A.C. Thomas, and J.H. Campbell Timecourse of fibrin deposition and removal after arterial injury Thromb. Res. 109 2003 65 69
16. M. Dewerchin, H.R. Lijnen, B. Van Hoef, F. De Cock, and D. Collen Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin Eur. J. Biochem. 185 1989 141 149
17. J.J. Zara, R.D. Wood, P. Boon, C.H. Kim, N. Pomato, R. Bredehorst, and C.W. Vogel A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates Anal. Biochem. 194 1991 156 162
18. F.M. Uckun, D.E. Myers, J.D. Irvin, V.M. Kuebelbeck, D. Finnegan, L.M. Chelstrom, and L.L. Houston Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin Leuk. Lymphoma 9 1993 459 476
19. O.H. Brekke, and I. Sandlie Therapeutic antibodies for human diseases at the dawn of the twenty-first century Nat. Rev., Drug Discov. 2 2003 52 62
20. M. Poon, S.O. Marx, R. Gallo, J.J. Badimon, M.B. Taubman, and A.R. Marks Rapamycin inhibits vascular smooth muscle cell migration J. Clin. Invest. 98 1996 2277 2283
21. M. Roque, E.D. Reis, C. Cordon-Cardo, M.B. Taubman, J.T. Fallon, V. Fuster, and J.J. Badimon Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model Lab. Invest. 81 2001 895 903
22. M.R. Mehra, and P.A. Uber TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit? J. Heart Lung Transplant. 22 2003 501 504
23. G.J. Murphy, and M.L. Nicholson Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early allograft vasculopathy J. Thorac. Cardiovasc. Surg. 126 2003 2058 2064
24. C.R. Gregory, X. Huang, R.E. Pratt, V.J. Dzau, R. Shorthouse, M.E. Billingham, and R.E. Morris Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement Transplantation 59 1995 655 661
25. S.E. Burke, N.L. Lubbers, Y.-W. Chen, G.C. Hsieh, K.W. Mollison, J.R. Luly, and C.D. Wegner Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin J. Cardiovasc. Pharmacol. 33 1999 829 835
26. D.J. Tyrrell, S. Kilfeather, and C.P. Page Therapeutic uses of heparin beyond its traditional role as an anticoagulant Trends Pharmacol. Sci. 16 1995 198 204
27. R.W. Jeanloz The chemistry of heparin Adv. Exp. Med. Biol. 52 1975 3 17
28. N. Volpi "Fast moving" and "slow moving" heparins, dermatan sulfate, and chondroitin sulfate: qualitative and quantitative analysis by agarose-gel electrophoresis Carbohydr. Res. 247 1993 263 278
29. P.A.M. Joseph, H.G. Garg, B.T. Thompson, X. Liu, and C.A. Hales Influence of molecular weight, protein core and charge of native heparin fractions on pulmonary artery smooth muscle cell proliferation Biochem. Biophys. Res. Commun. 241 1997 18 23
30. R.J. Linhardt, H.M. Wang, and S.A. Ampofo New methodologies in heparin structure analysis and the generation of LMW heparins Adv. Exp. Med. Biol. 313 1992 37 47
31. D.J. O'Shannessy, M.J. Dobersen, and R.H. Quarles A novel procedure for labelling immunoglobulins by conjugation to oligosaccharide moieties Immunol. Lett. 8 1984 273 277
32. U. Heimgartner, B. Kozulic, and K. Mosbach Reversible and irreversible cross-linking of immunoglobulin heavy chains through their carbohydrate residues Biochem. J. 267 1990 585 591
33. J.V. Staros, R.W. Wright, and D.M. Swingle Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions Anal. Biochem. 156 1986 220 222
34. A.C. Thomas, and J.H. Campbell Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis Atherosclerosis 176 2004 73 81
35. 165 gene transfer Circulation 94 1996 3291 3302
36. A.C. Thomas, and J.H. Campbell Differences in response of rat and rabbit arteries to injury Biomed. Res. 11 2000 189 196
37. M. Heras, J.J. Chesebro, W.J. Penny, K.R. Bailey, L. Badimon, and V. Fuster Effects of thrombin inhibition of the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor Circulation 79 1989 657 665
38. M.A. John, M.J. Elms, E.J. O'Reilly, D.B. Rylatt, P.G. Bundesen, and C.J. Hillyard The simpliRED D dimer test: a novel assay for the detection of crosslinked fibrin degradation products in whole blood Thromb. Res. 58 1990 273 281
39. S.R. Gundry, M.D. Klein, R.A. Drongowski, and M.M. Kirsh Clinical evaluation of a new rapid heparin assay using the dye azure A Am. J. Surg. 148 1984 191 194
40. S. Chandrasekhar, M.A. Esterman, and H.A. Hoffman Microdetermination of proteoglycans and glycosaminoglycans in the presence of guanidine hydrochloride Anal. Biochem. 161 1987 103 108
41. H.J. Moller, D. Heinegard, and J.H. Poulsen Combined alcian blue and silver staining of subnanogram quantities of proteoglycans and glycosaminoglycans in sodium dodecyl sulfate-polyacrylamide gels Anal. Biochem. 209 1993 169 175
42. K.L. Napoli A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection Clin. Ther. 22 Suppl. B 2000 B14 B24
43. J. Carlsson, H. Drevin, and R. Axén Protein thiolation and reversible protein-protein conjugation. N-succinimidyl 3-(2-pyridyldithio) propionate, a new heterobifunctional reagent Biochem. J. 173 1978 723 737
44. C. Bode, G.R. Matsueda, K.Y. Hui, and E. Haber Antibody-directed urokinase: a specific fibrinolytic agent Science 229 1985 765 767
45. O. Larm, R. Larsson, and P. Olsson A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue Biomater. Med. Dev. Artif. Organs 11 1983 161 173
46. Pierce Chemical Company Website. http://www.piercenet.com.
47. J.F. Liang, Y.T. Li, M.E. Connell, and V.C. Yang Synthesis and characterization of positively charged tPA as a prodrug using a heparin/protamine-based drug-delivery system AAPS Pharmsci. 2 2000 E7
48. Z. Grabarek, and J. Gergely Zero-length crosslinking procedure with the use of active esters Anal. Biochem. 185 1990 131 135
49. S.C. Gertz, W.L. Barry, L.W. Gimple, S. Banai, L.S. Perez, C.A. McNamara, E.R. Powers, M. Ragosta, G.K. Owens, W.C. Roberts, and I.J. Sarembock Predictors of luminal narrowing by neointima after angioplasty in atherosclerotic rabbits Cardiovasc. Res. 36 1997 396 407
50. L.W. Gimple, S.D. Hertz, H.L. Haber, M. Ragosta, E.R. Powers, W.C. Roberts, and I.J. Sarembock Effect of chronic subcutaneous or intramural administration of heparin on femoral artery restenosis after balloon angioplasty in hypercholesterolemic rabbits. A quantitative angiographic and histopathological study Circulation 86 1992 1536 1546
51. J.A. Bingley, I.P. Hayward, J.H. Campbell, and G.R. Campbell Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotypic change in vitro and neointimal formation in vivo J. Vasc. Surg. 28 1998 308 318
52. B.D. Klugherz, G. Llanos, W. Lieuallen, G.A. Kopia, G. Papandreou, P. Narayan, B. Sasseen, S.J. Adelman, R. Falotico, and R.L. Wilensky Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent Coron. Artery Dis. 13 2002 183 188
53. M. Degertekin, P.W. Serruys, D.P. Foley, K. Tanabe, E. Regar, J. Vos, P.C. Smits, W.J. van der Giessen, M. van den Brand, P. de Feyter, and J.J. Popma Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation Circulation 106 2002 1610 1613
54. E. Regar, P.W. Serruys, C. Bode, C. Holubarsch, J.L. Guermonprez, W. Wijns, A. Bartorelli, C. Constantini, M. Degertekin, K. Tanabe, C. Disco, E. Wuelfert, and M.C. Morice Angiographic findings of the multicenter randomized study with the sirolimus-eluting Bx velocity balloon-expendable stent (RAVEL). Sirolimus-eluting stents inhibit restenosis irrespective of the vessel size Circulation 106 2002 1949 1956
55. S.S. Wong Chemistry of Protein Conjugation and Cross-linking 1991 CRC Press Boca Raton, USA
56. R. Gorodetsky, A. Vexler, M. Shamir, J. An, L. Levdansky, I. Shimeliovich, and G. Marx New cell attachment peptide sequences from conserved epitopes in the carboxy termini of fibrinogen Exp. Cell Res. 287 2003 116 129
57. G. Bautovich, S. Angelides, F.T. Lee, R. Greenough, P. Bundesen, P. Murray, P. Schmidt, R. Waugh, J. Harris, K. Cameron, R.M. Lambrecht, and A. Basten Detection of deep venous thrombi and pulmonary embolus with technetium-99m-DD-3B6/22 anti-fibrin monoclonal antibody Fab' fragment J. Nucl. Med. 35 1994 195 202
58. J.F. Liang, Y.J. Park, H. Song, Y.T. Li, and V.C.-M. Yang ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs J. Control. Release 72 2001 145 156
59. J.F. Liang, H. Song, Y.T. Li, and V.C. Yang A novel heparin/protamine- based pro-drug type delivery system for protease drugs J. Pharm. Sci. 89 2000 664 673
60. M.R. Ward, G. Pasterkamp, A.C. Yeung, and C. Borst Arterial remodeling. Mechanisms and clinical implications Circulation 102 2000 1186 1191
61. T. Clackson, Chemistry and biology of sirolimus analogs, http://www.tctmd.com/expert-presentations.
62. A. Colombo, D. Orlic, G. Stankovic, N. Corvaja, V. Spanos, M. Montorfano, F. Liistro, M. Carlino, F. Airoldi, A. Chieffo, and C. Di Mario Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation Circulation 107 2003 2179 2180
63. G. Guagliumi, A. Farb, G. Musumeci, O. Valsecchi, M. Tespili, T. Motta, and R. Virmani Sirolimus-eluting stent implanted in human coronary artery for 16 months. Pathological findings Circulation 107 2003 1340 1341
64. Wyeth Pharmaceutical, Correction of drug information release, http://www.wyeth.com.
65. K. Tanabe, P.W. Serruys, M. Degertekin, E. Regar, R.T. van Domburg, J.E. Sousa, E. Wulfert, and M.-C. Morice Fate of side branches after coronary arterial sirolimus-eluting stent implantation Am. J. Cardiol. 90 2002 937 941